Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
66.5M
-
Number of holders
-
68
-
Total 13F shares, excl. options
-
53.5M
-
Shares change
-
-3.24M
-
Total reported value, excl. options
-
$84.5M
-
Value change
-
-$5.13M
-
Put/Call ratio
-
0.51
-
Number of buys
-
28
-
Number of sells
-
-27
-
Price
-
$1.58
Significant Holders of Regulus Therapeutics Inc. - Common Stock, par value $0.001 per share (RGLS) as of Q4 2024
84 filings reported holding RGLS - Regulus Therapeutics Inc. - Common Stock, par value $0.001 per share as of Q4 2024.
Regulus Therapeutics Inc. - Common Stock, par value $0.001 per share (RGLS) has 68 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 53.5M shares
of 66.5M outstanding shares and own 80.46% of the company stock.
Largest 10 shareholders include FEDERATED HERMES, INC. (12.9M shares), NEA Management Company, LLC (6.47M shares), Vivo Capital, LLC (5M shares), Octagon Capital Advisors LP (4.85M shares), BlackRock, Inc. (4.24M shares), VANGUARD GROUP INC (3.97M shares), Deep Track Capital, LP (3.26M shares), MILLENNIUM MANAGEMENT LLC (2.19M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (2M shares), and GEODE CAPITAL MANAGEMENT, LLC (1.28M shares).
This table shows the top 68 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.